Ashley Mansell

Company: Bacainn Therapeutics/Hudson Institute of Medical Research

Job title: Senior Director of Research & Development/Principal Investigator

Seminars:

BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation 11:30 am

BT032 is a novel first in class NLRP1 and NLRP3 inhibitor BT032 directly targets NLRP1 and NLRP3 activity BT032 reduces IAV-induced pulmonary inflammation in vivoRead more

day: Day 1 - Track B - Morning